loading
loading
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in Earnings Call Insights Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M Oct 28, 2026, 10:20 PM ETGlaukos Corporation (GKOS) StockAI-Generated Earnings Calls Insights Earnings Call Insights: Glaukos (GKOS) Q3 2026 Management View “Today, Glaukos reported record third quarter consolidated net sales of $211 million, up 58% versus the year ago quarter,” said (Chairman & CEO Thomas Burns), adding, “we are raising our full year 2026 net sales guidance to $775 million to $785 million.” Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result below Quick Insights Management cited strong current sales growth, major contributions from Epioxa and iDose TR rollouts, extensive scenario analysis including iDose LCD risks, and a confident path to $1 billion as the rationale for the early 2027 target. iDose TR's reimbursement policy, specifically LCD outcomes, creates risk; final decisions may affect sales, but management claims scenarios have been stress-tested and is preparing for varied policy outcomes. Epioxa saw rapid adoption, driving the majority of Corneal Health segment sales; about 90% of commercial lives and 80% of Medicaid lives have access, more than 200 care sites were established by Q3, but some operational frictions and payer-driven delays remain. Recommended For You
document fetched 2026-10-29 03:03 · canonical https://seekingalpha.com/news/4659813-glaukos-projects-1b-2027-revenue-as-it-raises-2026-net-sales-guidance-to-775m-785m?feed_item_type=news